Insmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease

Reuters

03/23

<a href="https://laohu8.com/S/INSM">Insmed</a> reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease

Insmed reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE 590 mg plus azithromycin 250 mg and ethambutol 15 mg/kg once daily versus placebo plus the same multidrug therapy in antibiotic-naive patients with a new occurrence of MAC lung infection.
The primary endpoint, change from baseline in Respiratory Symptom Score at Month 13, was 17.77 points with ARIKAYCE versus 14.66 points with placebo (p=0.0299).
Multiplicity-controlled secondary endpoints included culture conversion by Month 6 of 87.8% with ARIKAYCE versus 57.0% with placebo (p<0.0001).
Insmed said it plans to file a supplemental NDA for ARIKAYCE in the second half of 2026 and to submit the data to Japan’s PMDA in the second half of 2026 to support potential label changes.
The company said it plans to present the ENCORE data at a future medical congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230700PR_NEWS_USPR_____NY16178) on March 23, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2621777086"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621777086\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621777086?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777086","market":"nz","top_or_hot":-1,"title":"Insmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INSM\">Insmed</a> reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Insmed reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE 590 mg plus azithromycin 250 mg and ethambutol 15 mg/kg once daily versus placebo plus the same multidrug therapy in antibiotic-naive patients with a new occurrence of MAC lung infection.\n        </li>\n<li>\n          The primary endpoint, change from baseline in Respiratory Symptom Score at Month 13, was 17.77 points with ARIKAYCE versus 14.66 points with placebo (p=0.0299).\n        </li>\n<li>\n          Multiplicity-controlled secondary endpoints included culture conversion by Month 6 of 87.8% with ARIKAYCE versus 57.0% with placebo (p&lt;0.0001).\n        </li>\n<li>\n          Insmed said it plans to file a supplemental NDA for ARIKAYCE in the second half of 2026 and to submit the data to Japan’s PMDA in the second half of 2026 to support potential label changes.\n        </li>\n<li>\n          The company said it plans to present the ENCORE data at a future medical congress.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230700PR_NEWS_USPR_____NY16178) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-23 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INSM\">Insmed</a> reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Insmed reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE 590 mg plus azithromycin 250 mg and ethambutol 15 mg/kg once daily versus placebo plus the same multidrug therapy in antibiotic-naive patients with a new occurrence of MAC lung infection.\n        </li>\n<li>\n          The primary endpoint, change from baseline in Respiratory Symptom Score at Month 13, was 17.77 points with ARIKAYCE versus 14.66 points with placebo (p=0.0299).\n        </li>\n<li>\n          Multiplicity-controlled secondary endpoints included culture conversion by Month 6 of 87.8% with ARIKAYCE versus 57.0% with placebo (p&lt;0.0001).\n        </li>\n<li>\n          Insmed said it plans to file a supplemental NDA for ARIKAYCE in the second half of 2026 and to submit the data to Japan’s PMDA in the second half of 2026 to support potential label changes.\n        </li>\n<li>\n          The company said it plans to present the ENCORE data at a future medical congress.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230700PR_NEWS_USPR_____NY16178) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5qfctT:1","article_id":"2621777086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777086","pubTimestamp":1774263928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insmed reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE 590 mg plus azithromycin 250 mg and ethambutol 15 mg/kg once daily versus placebo plus the same multidrug therapy in antibiotic-naive patients with a new occurrence of MAC lung infection.The primary endpoint, change from baseline in Respiratory Symptom Score at Month 13, was 17.77 points with ARIKAYCE versus 14.66 points with placebo .Multiplicity-controlled secondary endpoints included culture conversion by Month 6 of 87.8% with ARIKAYCE versus 57.0% with placebo .Insmed said it plans to file a supplemental NDA for ARIKAYCE in the second half of 2026 and to submit the data to Japan’s PMDA in the second half of 2026 to support potential label changes.The company said it plans to present the ENCORE data at a future medical congress.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Insmed报告ARIKAYCE治疗MAC肺病的3b期ENCORE试验达到了主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"Insmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease\n    \n\n\n          Insmed reported positive topline results from the Phase 3b ENCORE study evaluating ARIKAYCE 590 mg plus azithromycin 250 mg and ethambutol 15 mg/kg once daily versus placebo plus the same multidrug therapy in antibiotic-naive patients with a new occurrence of MAC lung infection.\n        \n\n          The primary endpoint, change from baseline in Respiratory Symptom Score at Month 13, was 17.77 points with ARIKAYCE versus 14.66 points with placebo (p=0.0299).\n        \n\n          Multiplicity-controlled secondary endpoints included culture conversion by Month 6 of 87.8% with ARIKAYCE versus 57.0% with placebo (p<0.0001).\n        \n\n          Insmed said it plans to file a supplemental NDA for ARIKAYCE in the second half of 2026 and to submit the data to Japan’s PMDA in the second half of 2026 to support potential label changes.\n        \n\n          The company said it plans to present the ENCORE data at a future medical congress.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230700PR_NEWS_USPR_____NY16178) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}